Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use programme in France

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Houédé, Nadine ^a,b   Beuzeboc, Philippe ^c   Gourgou, Sophie ^d   Tosi, Diego ^d   Moise, Laura ^e   Gravis, Gwenaëlle ^f   Delva, Remy ^g   Fléchon, Aude ^h   Latorzeff, Igor ⁱ   Ferrero, Jean Marc ^j   Oudard, Stéphane ^k   Tartas, Sophie ^l   Laguerre, Brigitte ^m   Topart, Delphine ⁿ   Roubaud, Guilhem ^o   Agherbi, Hanane ^b   Rebillard, Xavier ^p   Azria, David ^b,d  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^c INSTITUT CURIE   (France)

^d CENTRE VAL D AURELLE   (France)

^e Haematology Institute   (France)

^f INSTITUT PAOLI CALMETTES   (France)

^g Paul Papin Cancer Center   (France)

^h CENTRE LÉON BÉRARD   (France)

ⁱ CLINIQUE PASTEUR   (France)

^j CENTRE ANTOINE LACASSAGNE   (France)

^k HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^l HOSPICES CIVILS DE LYON   (France)

^m CENTRE EUGÈNE MARQUIS   (France)

ⁿ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^o INSTITUT BERGONIÉ   (France)

^p Clinique Beau Soleil   (France)

more..

Author keywords

Abiraterone acetate; Efficacy; Metastatic castration resistant prostate cancer; Prognostic factor

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DOCETAXEL; ENZALUTAMIDE; ESTRAMUSTINE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FRANCE; GLEASON SCORE; HEALTH PROGRAM; HUMAN; HYPERTENSION; HYPOKALEMIA; LIVER DYSFUNCTION; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGNOSIS; RECOMMENDED DRUG DOSE; SURVIVAL TIME; TREATMENT DURATION; VERY ELDERLY; VISCERAL METASTASIS; CANCER GRADING; CLINICAL TRIAL; FOLLOW UP; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME;

ABIRATERONE ACETATE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FOLLOW-UP STUDIES; FRANCE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME;

EID: 84926663716     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1257-2     Document Type: Article

References (21)

1. Bahl A, Masson S, Birtle A, Chowdhury S, de Bono J. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. Cancer Treat Rev. 2014;40(1):170-7.
2. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242-5.
3. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-54.
4. Potter GA, Barrie SE, Jarman M, Rowlands MG. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem. 1995;38(13):2463-71.
5. Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005;96(9):1241-46.
6. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
7. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-59.
8. Culig Z, Santer FR. Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer. Steroids. 2013;78(9):851-9.
9. Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer. 2014;120(7):968-75.
10. Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol. 2013;24(7):1807-12.
11. Cai S, Wang H, Bailey B, Ernstberger A, Juliar BE, Sinn AL, et al. Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity. Clin Cancer Res. 2011;17(8):2195-206.
12. Montgomery B, Kheoh T, Molina A, Li J, Bellmunt J, Tran N, et al. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. Eur Urol. 2014;S0302-2838(14):00616-2.
13. Ryan CJ, Molina A, Li J, Kheoh T, Small EJ, Haqq CM, et al. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol. 2013;31(22):2791-8.
14. Burgio SL, Conteduca V, Rudnas B, Carrozza F, Campadelli E, Bianchi E, et al. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(1):39-43.
15. Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D, et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2014;25(3):657-62.
16. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424-33.
17. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-97.
18. van Soest RJ, van Royen ME, de Morree ES, Moll JM, Teubel W, Wiemer EA, et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer. 2013;49(18):3821-30.
19. Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E, et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. 2012;23(11):2943-7.
20. Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, et al. The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2014;66(4):646-52.
21. Sternberg CN, Castellano D, Daugaard G, Géczi L, Hotte SJ, Mainwaring PN, et al. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Lancet Oncol. 2014;15(11):1263-8.